🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 183 (from laksa147)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa183.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html\')), getAhrefsUnparsedNoserviceFromURL(\'https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html","crawl_time":1775145793,"first_indexed_time":0,"http_code":200,"src_unparsed":"ca,canada!health-infobase,\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html s443","src_root_hash":"10069666093540770583","history_drop_reason":null,"meta_title":"Long-term neuropsychiatric symptoms of COVID-19 among adults — Canada.ca","meta_descriptions":["Data from the Canadian COVID-19 Antibody and Health Survey - Cycle 2 April to August 2022."],"attrs_boilerpipe_text":"Most people will experience and recover from initial symptoms of COVID-19 illness. Some will develop ongoing symptoms more than 3 months after their COVID-19 infection\nFootnote\n1\n. Long-term symptoms of COVID-19 can be grouped into two major categories\nFootnote\n2\n,\nFootnote\n3\n:\ncardiopulmonary - related to the heart and lungs\nneuropsychiatric\n- related to the nervous system, cognitive function (such as thinking, reasoning, memory, and judgement) and mental health\nNeuropsychiatric symptoms are more common. Two-thirds of adults experiencing long-term symptoms of COVID-19 report neuropsychiatric symptoms.\nFor this survey, data on the following neuropsychiatric symptoms were collected:\ndifficulty thinking and solving problems (brain fog)\nstress or anxiety\nsadness, negativity, hopelessness, or depression\nheadache\nloss of taste or smell\nThere are other long-term neuropsychiatric symptoms of COVID-19 not captured in the survey. These 5 are the most commonly reported symptoms.\nRate of long-term neuropsychiatric symptoms of COVID-19\nMore than 1 in 10 (11.3%, weighted count of 902,700) adults experienced long-term neuropsychiatric symptoms (Table 1).\nRate by socio-demographic group\nWe examined the rate of long-term neuropsychiatric symptoms across different socio-demographic groups.\nAge\nA similar percentage of adults across age groups reported long-term neuropsychiatric symptoms. People aged 50 to 64 had the highest rate (12.5%). Differences between age groups were not statistically significant (Table 1).\nSex\nFemales (14.5%) were 1.8 times more likely to report long-term neuropsychiatric symptoms than males (8.2%) (Table 1).\nEthnoracial group\nThe Indigenous identity group had the highest rate of long-term neuropsychiatric symptoms (21.2%) (Table 1). The rate was:\n1.8 times higher than the Non-racialized group (11.9%)\n2.5 times higher than the Racialized group (8.4%)\nTable 1. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by socio-demographic characteristics.\nTable 1. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by socio-demographic characteristics.\nCharacteristic\nPercentage reporting long-term neuropsychiatric symptoms of COVID-19 (%)\n95% Confidence interval (CI)\nWeighted count ** (n)\nOverall rate\n11.3\n10.3-12.4\n902,700\nAge (years)\n18-34\n11.1\n9.1-13.1\n326,500\n35-49\n10.9\n9.2-12.7\n270,400\n50-64\n12.5\n10.4-14.5\n226,500\n65+\n10.8\n8.0-13.6\n79,200\nSex\nFemale\n14.5\n12.9-16.1\n576,800\nMale\n8.2\n6.8-9.6\n325,900\nEthnoracial group\nIndigenous identity group\n21.2\n13.7-28.7\n57,200\nNon-racialized group\n§\n11.9\n10.7-13.2\n667,200\nRacialized group\n¥\n8.4\n6.2-10.6\n175,900\n§\nNon-racialized group- all respondents who identified as White, excluding those who identified as Indigenous\n¥\nRacialized group- all respondents who did not identify as Indigenous or White\n** Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\nAmong adults with a history of mental health condition or chronic neurological disorder\nAdults were more likely to report long-term neuropsychiatric symptoms if they had a history of:\nmental health condition (e.g., depression, anxiety)\nchronic neurological disorder (e.g., Alzheimer's disease or other dementia, and other neurological conditions)\nThe percentage reporting long-term neuropsychiatric symptoms was:\n2.0 times higher among those with a history of mental health condition (20.3%) than those without a history (10.2%)\n2.4 times higher among those with a history of chronic neurological disorder (26.3%\nE\n) than those without a history (11.1%) (Table 2)\nTable 2. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by history of mental health condition or chronic neurological disorder.\nTable 2. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by history of mental health condition or chronic neurological disorder.\nHaving a history of\nResponse\nPercentage reporting long-term neuropsychiatric symptoms of COVID-19 (%)\n95% Confidence Interval (CI)\nWeighted count** (n)\nMental health condition\nYes\n20.3\n16.4-24.6\n183,000\nNo\n10.2\n9.1-11.4\n719,700\nChronic neurological disorder\nYes\n26.3\nE\n14.7-41.0\nE\n31,500\nNo\n11.1\n10.1-12.2\n871,200\n** Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\nE\nResults should be interpreted with caution due to high sampling variability.\nAmong adults with difficulties accessing healthcare\nThe survey asked respondents if they had difficulties accessing healthcare services in the last 12 months. Across most categories, adults  who experienced difficulties were more likely to report long-term neuropsychiatric symptoms (Table 3).\nThe percentage reporting long-term neuropsychiatric symptoms was 2.2 times higher among those who had any difficulty accessing healthcare services (17.0%) than those who did not (7.6%) (Table 3).\nThe most common difficulties were:\nlack of availability of culturally appropriate health services (25.3%\nE\n)\ncost issues (23.1%\nE\n)\ntransportation issues (23.0%\nE\n)\nunavailability of healthcare services in the residential area (22.4%)\nTable 3. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by difficulties accessing healthcare services.\nTable 3. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by difficulties accessing healthcare services.\nDifficulties accessing healthcare services\nResponse\nPercentage reporting long-term neuropsychiatric symptoms of COVID-19 (%)\n95% Confidence Interval (CI)\nWeighted count** (n)\nAny difficulty\nYes\n17.0\n15.0-19.1\n537,800\nNo\n7.6\n6.5-8.8\n364,900\nLack of availability of culturally appropriate health services\nYes\n25.3\nE\n11.2-44.7\nE\n18,800\nNo\n11.4\n10.3-12.5\n863,100\nCost issues\nYes\n23.1\nE\n16.3-31.2\nE\n89,900\nNo\n10.9\n9.8-12.0\n792,000\nTransportation issues\nYes\n23.0\nE\n13.1-35.6\nE\n31,300\nNo\n11.3\n10.2-12.4\n850,600\nNot available in my area\nYes\n22.4\n16.5-29.3\n92,000\nNo\n10.9\n9.8-12.0\n789,900\nQuarantine or office closures\nYes\n21.0\n16.7-25.9\n191,500\nNo\n10.2\n9.2-11.3\n690,300\nAppointment cancellation, delay or rescheduling due to non-COVID-19 pandemic reasons\nYes\n20.3\n14.8-26.8\n117,000\nNo\n10.8\n9.7-11.9\n764,800\nAppointment cancellation, delay or rescheduling due to COVID-19 pandemic\nYes\n19.3\n16.0-22.9\n285,500\nNo\n9.6\n8.5-10.8\n596,300\nWaited too long between booking appointments and services\nYes\n18.0\n14.9-21.4\n252,400\nNo\n10.0\n8.9-11.2\n629,500\nDifficulty getting a referral\nYes\n16.3\n12.6-20.6\n134,500\nNo\n10.9\n9.8-12.1\n747,400\n** Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\nE\nResults should be interpreted with caution due to high sampling variability.\nSeverity of COVID-19 symptoms\nAdults with more severe initial COVID-19 symptoms were more likely to have long-term neuropsychiatric symptoms (Table 4). The percentage of those who had long-term neuropsychiatric symptoms was:\n27.8% among those who reported severe COVID-19 symptoms\n11.5% among those who reported moderate COVID-19 symptoms\n4.4% among those who reported mild COVID-19 symptoms\nTable 4. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by severity of initial COVID-19 symptoms.\nTable 4. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by severity of initial COVID-19 symptoms.\nImpact of COVID-19\nResponse\nPercentage reporting long-term neuropsychiatric symptoms of COVID-19 (%)\n95% Confidence Interval (CI)\nWeighted count** (n)\nSeverity of initial COVID-19 symptoms\nMild symptoms- no effect on daily life\n4.4\n3.3-5.7\n114,000\nModerate symptoms- some effect on daily life\n11.5\n9.8-13.3\n391,100\nSevere symptoms- significant effect on daily life\n27.8\n24.3-31.6\n386,400\n** Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\nSubset population with neuropsychiatric symptoms\nThe data below come from the subset of people who experienced neuropsychiatric symptoms of COVID-19. This is different from other data in this blog, which come from the larger group of people with a COVID-19 infection 3 or more months prior to the survey.\nLimitations to daily activities from COVID-19 symptoms\nThe survey asked about limitations to daily activities from COVID-19 symptoms. 1 in 4 (23.8%) adults with long-term neuropsychiatric symptoms were often or always limited in daily activities by their symptoms (Table 5).\nAccessing healthcare for COVID-19 symptoms\nSome respondents reported difficulty accessing healthcare (Table 3). These respondents were also asked about accessing healthcare services for COVID-19 symptoms. 4 in 10 (39.8%) adults with long-term neuropsychiatric symptoms reported experiencing difficulties (Table 5).\nTable 5. Percentage of adults with long-term neuropsychiatric symptoms of COVID-19 reporting limitations to daily activities due to COVID-19 symptoms and difficulties accessing healthcare for COVID-19 symptoms in the last 12 months.\nTable 5. Percentage of adults with long-term neuropsychiatric symptoms of COVID-19 reporting limitations to daily activities due to COVID-19 symptoms and difficulties accessing healthcare for COVID-19 symptoms in the last 12 months.\nImpact of COVID-19\nResponse\nPercentage (%)\n95% Confidence Interval (CI)\nWeighted Count** (n)\nLimitations to daily activities due to COVID-19 symptoms\nNever\n13.2\n9.9-17.0\n118,800\nRarely or sometimes\n6.7\n57.7-67.6\n566,300\nOften or always\n23.8\n19.8-28.2\n215,100\nDifficulties accessing healthcare services for COVID-19 symptoms in the last 12 months\nYes\n39.8\n33.4-46.9\n213,700\nNo\n60.2\n53.6-66.6\n323,600\n** Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\nOn May 5, 2023, the World Health Organization declared that COVID-19 is an established and ongoing health issue that no longer constitutes a global health threat. While it is no longer classified as a public health emergency, many people living in Canada continue to be affected by COVID-19. If you or someone close to you is experiencing long-term symptoms of COVID-19, including neuropsychiatric symptoms, it is important to talk to a health care provider.\nFor more information on long-term symptoms of COVID-19\nPost-COVID-19 condition (long COVID)\nCOVID-19 longer-term symptoms among Canadian adults\nCOVID-19 epidemiology update: Summary\nAbout the data\nThis blog uses national data from the\nCanadian COVID-19 Antibody and Health Survey (CCAHS) – Cycle 2\n, collected by Statistics Canada. The survey collected information between April and August 2022. Data is from adults 18 years and older living in Canada. Unless otherwise noted, data is from adults who self-reported a COVID-19 infection 3 or more months before the survey. COVID-19 infections could be confirmed by a test or suspected from experienced symptoms or known exposures.\nA weight was assigned to each respondent of the survey, so the results accurately represent the Canadian population. A\nweighted count\nuses these assigned weights and is not the actual number of survey respondents.\nPopulations excluded from the CCAHS-2 were people:\nliving in the three territories\nless than 18 years old\nliving on reserves and other Indigenous settlements in the provinces\nliving in institutions\nfull-time members of the Canadian Forces living on base\nresidents in certain remote regions\nFor more information on the CCAHS-2, visit\nCanadian COVID-19 Antibody and Health Survey (CCAHS)-Cycle 2\n.\nSuggested citation\nLong-term neuropsychiatric symptoms of COVID-19 among adults. Data from the Canadian COVID-19 Antibody and Health Survey – Cycle 2 April to August 2022. Public Health Agency of Canada, Centre for Surveillance and Applied Research. 2024.\nThank you for your feedback\nDate modified:\n2024-10-30","attrs_markdown":"- [Skip to main content](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#wb-cont)\n- [Skip to \"About government\"](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#wb-info)\n\n## Language selection\n- [Français](https:\/\/sante-infobase.canada.ca\/labo-de-donnees\/symptomes-neuropsychiatriques-syndrome-post-covid.html)\n\n[![](https:\/\/health-infobase.canada.ca\/src\/GCWeb\/assets\/sig-blk-en.svg) Government of Canada \/ Gouvernement du Canada](https:\/\/www.canada.ca\/en.html)\n\n## Search\n\n## You are here:\n1. [Canada.ca](https:\/\/www.canada.ca\/en.html)\n2. [Health](https:\/\/www.canada.ca\/en\/services\/health.html)\n3. [Health science, research and data](https:\/\/www.canada.ca\/en\/services\/health\/science-research-data.html)\n4. [Health Infobase](https:\/\/health-infobase.canada.ca\/)\n\n# Long-term neuropsychiatric symptoms of COVID-19 among adults:Data blog\nData from the Canadian COVID-19 Antibody and Health Survey - Cycle 2 April to August 2022.\n\n- Last updated: 2024-10-30\n\n![COVID icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/COVID3.png)\n\nMost people will experience and recover from initial symptoms of COVID-19 illness. Some will develop ongoing symptoms more than 3 months after their COVID-19 infection[Footnote 1](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn1 \"Post-COVID-19 condition. Annual Review of Medicine.\"). Long-term symptoms of COVID-19 can be grouped into two major categories[Footnote2](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn2 \"Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The Lancet Psychiatry. 2022 Oct 1;9(10):815-27.\"),[Footnote 3](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn3 \"Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness. The Lancet Respiratory Medicine. 2023 Aug 1;11(8):726-38.\"):\n\n- cardiopulmonary - related to the heart and lungs\n- **neuropsychiatric** - related to the nervous system, cognitive function (such as thinking, reasoning, memory, and judgement) and mental health\n\nNeuropsychiatric symptoms are more common. Two-thirds of adults experiencing long-term symptoms of COVID-19 report neuropsychiatric symptoms.\n***\n![COVID icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/COVID2.png)\n\n## About long-term neuropsychiatric symptoms of COVID-19\nFor this survey, data on the following neuropsychiatric symptoms were collected:\n\n- difficulty thinking and solving problems (brain fog)\n- stress or anxiety\n- sadness, negativity, hopelessness, or depression\n- headache\n- loss of taste or smell\n\nThere are other long-term neuropsychiatric symptoms of COVID-19 not captured in the survey. These 5 are the most commonly reported symptoms.\n***\n![population icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/population2.png)\n\n## Rate of long-term neuropsychiatric symptoms of COVID-19\nMore than 1 in 10 (11.3%, weighted count of 902,700) adults experienced long-term neuropsychiatric symptoms (Table 1).\n\n### Rate by socio-demographic group\nWe examined the rate of long-term neuropsychiatric symptoms across different socio-demographic groups.\n\n#### Age\nA similar percentage of adults across age groups reported long-term neuropsychiatric symptoms. People aged 50 to 64 had the highest rate (12.5%). Differences between age groups were not statistically significant (Table 1).\n\n#### Sex\nFemales (14.5%) were 1.8 times more likely to report long-term neuropsychiatric symptoms than males (8.2%) (Table 1).\n\n#### Ethnoracial group\nThe Indigenous identity group had the highest rate of long-term neuropsychiatric symptoms (21.2%) (Table 1). The rate was:\n\n- 1\\.8 times higher than the Non-racialized group (11.9%)\n- 2\\.5 times higher than the Racialized group (8.4%)\n\nTable 1. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by socio-demographic characteristics.\n\n| Characteristic | Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) | 95% Confidence interval (CI) | Weighted count \\*\\* (n) |   |\n|---|---|---|---|---|\n| **Overall rate** | 11\\.3 | 10\\.3-12.4 | 902,700 |   |\n| Age (years) | 18-34 | 11\\.1 | 9\\.1-13.1 | 326,500 |\n| 35-49 | 10\\.9 | 9\\.2-12.7 | 270,400 |   |\n| 50-64 | 12\\.5 | 10\\.4-14.5 | 226,500 |   |\n| 65+ | 10\\.8 | 8\\.0-13.6 | 79,200 |   |\n| Sex | Female | 14\\.5 | 12\\.9-16.1 | 576,800 |\n| Male | 8\\.2 | 6\\.8-9.6 | 325,900 |   |\n| Ethnoracial group | Indigenous identity group | 21\\.2 | 13\\.7-28.7 | 57,200 |\n| Non-racialized group§ | 11\\.9 | 10\\.7-13.2 | 667,200 |   |\n| Racialized group¥ | 8\\.4 | 6\\.2-10.6 | 175,900 |   |\n\n§ Non-racialized group- all respondents who identified as White, excluding those who identified as Indigenous\n\n¥ Racialized group- all respondents who did not identify as Indigenous or White\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n***\n![medical chart icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/medicalchart.png)\n\n## Among adults with a history of mental health condition or chronic neurological disorder\nAdults were more likely to report long-term neuropsychiatric symptoms if they had a history of:\n\n- mental health condition (e.g., depression, anxiety)\n- chronic neurological disorder (e.g., Alzheimer's disease or other dementia, and other neurological conditions)\n\nThe percentage reporting long-term neuropsychiatric symptoms was:\n\n- 2\\.0 times higher among those with a history of mental health condition (20.3%) than those without a history (10.2%)\n- 2\\.4 times higher among those with a history of chronic neurological disorder (26.3%E) than those without a history (11.1%) (Table 2)\n\nTable 2. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by history of mental health condition or chronic neurological disorder.\n\n| Having a history of | Response | Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) | 95% Confidence Interval (CI) | Weighted count\\*\\* (n) |\n|---|---|---|---|---|\n| Mental health condition | Yes | 20\\.3 | 16\\.4-24.6 | 183,000 |\n| No | 10\\.2 | 9\\.1-11.4 | 719,700 |   |\n| Chronic neurological disorder | Yes | 26\\.3E | 14\\.7-41.0E | 31,500 |\n| No | 11\\.1 | 10\\.1-12.2 | 871,200 |   |\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n\nE Results should be interpreted with caution due to high sampling variability.\n***\n![hospital icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/hospital.png)\n\n## Among adults with difficulties accessing healthcare\nThe survey asked respondents if they had difficulties accessing healthcare services in the last 12 months. Across most categories, adults who experienced difficulties were more likely to report long-term neuropsychiatric symptoms (Table 3).\n\nThe percentage reporting long-term neuropsychiatric symptoms was 2.2 times higher among those who had any difficulty accessing healthcare services (17.0%) than those who did not (7.6%) (Table 3).\n\nThe most common difficulties were:\n\n- lack of availability of culturally appropriate health services (25.3%E)\n- cost issues (23.1%E)\n- transportation issues (23.0%E)\n- unavailability of healthcare services in the residential area (22.4%)\n\nTable 3. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by difficulties accessing healthcare services.\n\n| Difficulties accessing healthcare services | Response | Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) | 95% Confidence Interval (CI) | Weighted count\\*\\* (n) |\n|---|---|---|---|---|\n| Any difficulty | Yes | 17\\.0 | 15\\.0-19.1 | 537,800 |\n| No | 7\\.6 | 6\\.5-8.8 | 364,900 |   |\n| Lack of availability of culturally appropriate health services | Yes | 25\\.3E | 11\\.2-44.7E | 18,800 |\n| No | 11\\.4 | 10\\.3-12.5 | 863,100 |   |\n| Cost issues | Yes | 23\\.1E | 16\\.3-31.2E | 89,900 |\n| No | 10\\.9 | 9\\.8-12.0 | 792,000 |   |\n| Transportation issues | Yes | 23\\.0E | 13\\.1-35.6E | 31,300 |\n| No | 11\\.3 | 10\\.2-12.4 | 850,600 |   |\n| Not available in my area | Yes | 22\\.4 | 16\\.5-29.3 | 92,000 |\n| No | 10\\.9 | 9\\.8-12.0 | 789,900 |   |\n| Quarantine or office closures | Yes | 21\\.0 | 16\\.7-25.9 | 191,500 |\n| No | 10\\.2 | 9\\.2-11.3 | 690,300 |   |\n| Appointment cancellation, delay or rescheduling due to non-COVID-19 pandemic reasons | Yes | 20\\.3 | 14\\.8-26.8 | 117,000 |\n| No | 10\\.8 | 9\\.7-11.9 | 764,800 |   |\n| Appointment cancellation, delay or rescheduling due to COVID-19 pandemic | Yes | 19\\.3 | 16\\.0-22.9 | 285,500 |\n| No | 9\\.6 | 8\\.5-10.8 | 596,300 |   |\n| Waited too long between booking appointments and services | Yes | 18\\.0 | 14\\.9-21.4 | 252,400 |\n| No | 10\\.0 | 8\\.9-11.2 | 629,500 |   |\n| Difficulty getting a referral | Yes | 16\\.3 | 12\\.6-20.6 | 134,500 |\n| No | 10\\.9 | 9\\.8-12.1 | 747,400 |   |\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n\nE Results should be interpreted with caution due to high sampling variability.\n***\n![severity icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/time1.png)\n\n## Severity of COVID-19 symptoms\nAdults with more severe initial COVID-19 symptoms were more likely to have long-term neuropsychiatric symptoms (Table 4). The percentage of those who had long-term neuropsychiatric symptoms was:\n\n- 27\\.8% among those who reported severe COVID-19 symptoms\n- 11\\.5% among those who reported moderate COVID-19 symptoms\n- 4\\.4% among those who reported mild COVID-19 symptoms\n\nTable 4. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by severity of initial COVID-19 symptoms.\n\n| Impact of COVID-19 | Response | Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) | 95% Confidence Interval (CI) | Weighted count\\*\\* (n) |\n|---|---|---|---|---|\n| Severity of initial COVID-19 symptoms | Mild symptoms- no effect on daily life | 4\\.4 | 3\\.3-5.7 | 114,000 |\n| Moderate symptoms- some effect on daily life | 11\\.5 | 9\\.8-13.3 | 391,100 |   |\n| Severe symptoms- significant effect on daily life | 27\\.8 | 24\\.3-31.6 | 386,400 |   |\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n***\n![population icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/subset.png)\n\n## Subset population with neuropsychiatric symptoms\nThe data below come from the subset of people who experienced neuropsychiatric symptoms of COVID-19. This is different from other data in this blog, which come from the larger group of people with a COVID-19 infection 3 or more months prior to the survey.\n\n### Limitations to daily activities from COVID-19 symptoms\nThe survey asked about limitations to daily activities from COVID-19 symptoms. 1 in 4 (23.8%) adults with long-term neuropsychiatric symptoms were often or always limited in daily activities by their symptoms (Table 5).\n\n### Accessing healthcare for COVID-19 symptoms\nSome respondents reported difficulty accessing healthcare (Table 3). These respondents were also asked about accessing healthcare services for COVID-19 symptoms. 4 in 10 (39.8%) adults with long-term neuropsychiatric symptoms reported experiencing difficulties (Table 5).\n\nTable 5. Percentage of adults with long-term neuropsychiatric symptoms of COVID-19 reporting limitations to daily activities due to COVID-19 symptoms and difficulties accessing healthcare for COVID-19 symptoms in the last 12 months.\n\n| Impact of COVID-19 | Response | Percentage (%) | 95% Confidence Interval (CI) | Weighted Count\\*\\* (n) |\n|---|---|---|---|---|\n| Limitations to daily activities due to COVID-19 symptoms | Never | 13\\.2 | 9\\.9-17.0 | 118,800 |\n| Rarely or sometimes | 6\\.7 | 57\\.7-67.6 | 566,300 |   |\n| Often or always | 23\\.8 | 19\\.8-28.2 | 215,100 |   |\n| Difficulties accessing healthcare services for COVID-19 symptoms in the last 12 months | Yes | 39\\.8 | 33\\.4-46.9 | 213,700 |\n| No | 60\\.2 | 53\\.6-66.6 | 323,600 |   |\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n***\n![medical help icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/help.png)\n\nOn May 5, 2023, the World Health Organization declared that COVID-19 is an established and ongoing health issue that no longer constitutes a global health threat. While it is no longer classified as a public health emergency, many people living in Canada continue to be affected by COVID-19. If you or someone close to you is experiencing long-term symptoms of COVID-19, including neuropsychiatric symptoms, it is important to talk to a health care provider.\n## For more information on long-term symptoms of COVID-19\n- [Post-COVID-19 condition (long COVID)](https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/2019-novel-coronavirus-infection\/symptoms\/post-covid-19-condition.html)\n- [COVID-19 longer-term symptoms among Canadian adults](https:\/\/health-infobase.canada.ca\/covid-19\/post-covid-condition\/)\n- [COVID-19 epidemiology update: Summary](https:\/\/health-infobase.canada.ca\/covid-19\/)\n## About the data\nThis blog uses national data from the [Canadian COVID-19 Antibody and Health Survey (CCAHS) – Cycle 2](https:\/\/www.statcan.gc.ca\/en\/survey\/household\/5339), collected by Statistics Canada. The survey collected information between April and August 2022. Data is from adults 18 years and older living in Canada. Unless otherwise noted, data is from adults who self-reported a COVID-19 infection 3 or more months before the survey. COVID-19 infections could be confirmed by a test or suspected from experienced symptoms or known exposures.\n\nA weight was assigned to each respondent of the survey, so the results accurately represent the Canadian population. A **weighted count** uses these assigned weights and is not the actual number of survey respondents.\n\nPopulations excluded from the CCAHS-2 were people:\n\n- living in the three territories\n- less than 18 years old\n- living on reserves and other Indigenous settlements in the provinces\n- living in institutions\n- full-time members of the Canadian Forces living on base\n- residents in certain remote regions\n\nFor more information on the CCAHS-2, visit [Canadian COVID-19 Antibody and Health Survey (CCAHS)-Cycle 2](https:\/\/www.statcan.gc.ca\/en\/survey\/household\/5339).\n\n### Suggested citation\nLong-term neuropsychiatric symptoms of COVID-19 among adults. Data from the Canadian COVID-19 Antibody and Health Survey – Cycle 2 April to August 2022. Public Health Agency of Canada, Centre for Surveillance and Applied Research. 2024.\n\n## References\nReference 1\n\nNalbandian A, Desai AD, Wan EY. Post-COVID-19 condition. Annual Review of Medicine. 2023 Jan 27; 74: 55-64.\n\n[Return to footnote 1 referrer](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn1-rf)\n\nReference 2\n\nTaquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, Harrison PJ. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The Lancet Psychiatry. 2022 Oct 1;9(10):815-27.\n\n[Return to first footnote 2 referrer](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn2-rf)\n\nReference 3\n\nPandharipande P, Roberson SW, Harrison FE, Wilson JE, Bastarache JA, Ely EW. Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness. The Lancet Respiratory Medicine. 2023 Aug 1;11(8):726-38.\n\n[Return to first footnote 3 referrer](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn3-rf)\n***\n## You might also be interested in\n![](https:\/\/health-infobase.canada.ca\/src\/img\/redesign\/covid.png)\n\n### [COVID-19: Longer-term symptoms among Canadian adults](https:\/\/health-infobase.canada.ca\/covid-19\/post-covid-condition\/)\nData on longer-term symptoms of COVID-19 in Canada.\n\n![](https:\/\/health-infobase.canada.ca\/src\/img\/redesign\/covid.png)\n\n### [COVID-19 epidemiology update: Summary](https:\/\/health-infobase.canada.ca\/covid-19\/)\nSummary of COVID-19 cases, hospitalizations and deaths, testing and variants of concern, and outbreaks across Canada.\n\n[All Health Infobase data products](https:\/\/health-infobase.canada.ca\/)\n\nThank you for your feedback\n\nDate modified:\n\n2024-10-30\n\n## About this site\n### [Health Infobase](https:\/\/health-infobase.canada.ca\/)\n- [Contact us by email](mailto:infobase@phac-aspc.gc.ca)\n\n### Government of Canada\n- [All Contacts](https:\/\/www.canada.ca\/en\/contact.html)\n- [Departments and agencies](https:\/\/www.canada.ca\/en\/government\/dept.html)\n- [About government](https:\/\/www.canada.ca\/en\/government\/system.html)\n#### Themes and topics\n- [Jobs](https:\/\/www.canada.ca\/en\/services\/jobs.html)\n- [Immigration and citizenship](https:\/\/www.canada.ca\/en\/services\/immigration-citizenship.html)\n- [Travel and tourism](https:\/\/travel.gc.ca\/)\n- [Business](https:\/\/www.canada.ca\/en\/services\/business.html)\n- [Benefits](https:\/\/www.canada.ca\/en\/services\/benefits.html)\n- [Health](https:\/\/www.canada.ca\/en\/services\/health.html)\n- [Taxes](https:\/\/www.canada.ca\/en\/services\/taxes.html)\n- [Environment and natural resources](https:\/\/www.canada.ca\/en\/services\/environment.html)\n- [National security and defence](https:\/\/www.canada.ca\/en\/services\/defence.html)\n- [Culture, history and sport](https:\/\/www.canada.ca\/en\/services\/culture.html)\n- [Policing, justice and emergencies](https:\/\/www.canada.ca\/en\/services\/policing.html)\n- [Transport and infrastructure](https:\/\/www.canada.ca\/en\/services\/transport.html)\n- [Canada and the world](https:\/\/international.gc.ca\/world-monde\/index.aspx?lang=eng)\n- [Money and finance](https:\/\/www.canada.ca\/en\/services\/finance.html)\n- [Science and innovation](https:\/\/www.canada.ca\/en\/services\/science.html)\n- [Indigenous peoples](https:\/\/www.canada.ca\/en\/services\/indigenous-peoples.html)\n- [Veterans and military](https:\/\/www.canada.ca\/en\/services\/veterans.html)\n- [Youth](https:\/\/www.canada.ca\/en\/services\/youth.html)\n\n### Government of Canada Corporate\n- [Social media](https:\/\/www.canada.ca\/en\/social.html)\n- [Mobile applications](https:\/\/www.canada.ca\/en\/mobile.html)\n- [About Canada.ca](https:\/\/www.canada.ca\/en\/government\/about.html)\n- [Terms and conditions](https:\/\/www.canada.ca\/en\/transparency\/terms.html)\n- [Privacy](https:\/\/www.canada.ca\/en\/transparency\/privacy.html)\n\n![Symbol of the Government of Canada](https:\/\/health-infobase.canada.ca\/src\/assets\/wmms-blk.svg)","attrs_readable_markdown":"![COVID icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/COVID3.png)\n\nMost people will experience and recover from initial symptoms of COVID-19 illness. Some will develop ongoing symptoms more than 3 months after their COVID-19 infection[Footnote 1](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn1 \"Post-COVID-19 condition. Annual Review of Medicine.\"). Long-term symptoms of COVID-19 can be grouped into two major categories[Footnote2](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn2 \"Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The Lancet Psychiatry. 2022 Oct 1;9(10):815-27.\"),[Footnote 3](https:\/\/health-infobase.canada.ca\/datalab\/post-covid-condition-neuropsychiatric-symptoms.html#fn3 \"Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness. The Lancet Respiratory Medicine. 2023 Aug 1;11(8):726-38.\"):\n\n- cardiopulmonary - related to the heart and lungs\n- **neuropsychiatric** - related to the nervous system, cognitive function (such as thinking, reasoning, memory, and judgement) and mental health\n\nNeuropsychiatric symptoms are more common. Two-thirds of adults experiencing long-term symptoms of COVID-19 report neuropsychiatric symptoms.\n***\n![COVID icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/COVID2.png)\n\nFor this survey, data on the following neuropsychiatric symptoms were collected:\n\n- difficulty thinking and solving problems (brain fog)\n- stress or anxiety\n- sadness, negativity, hopelessness, or depression\n- headache\n- loss of taste or smell\n\nThere are other long-term neuropsychiatric symptoms of COVID-19 not captured in the survey. These 5 are the most commonly reported symptoms.\n***\n![population icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/population2.png)\n\n## Rate of long-term neuropsychiatric symptoms of COVID-19\nMore than 1 in 10 (11.3%, weighted count of 902,700) adults experienced long-term neuropsychiatric symptoms (Table 1).\n\n### Rate by socio-demographic group\nWe examined the rate of long-term neuropsychiatric symptoms across different socio-demographic groups.\n\n#### Age\nA similar percentage of adults across age groups reported long-term neuropsychiatric symptoms. People aged 50 to 64 had the highest rate (12.5%). Differences between age groups were not statistically significant (Table 1).\n\n#### Sex\nFemales (14.5%) were 1.8 times more likely to report long-term neuropsychiatric symptoms than males (8.2%) (Table 1).\n\n#### Ethnoracial group\nThe Indigenous identity group had the highest rate of long-term neuropsychiatric symptoms (21.2%) (Table 1). The rate was:\n\n- 1\\.8 times higher than the Non-racialized group (11.9%)\n- 2\\.5 times higher than the Racialized group (8.4%)\n\nTable 1. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by socio-demographic characteristics.\n\n| Characteristic | Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) | 95% Confidence interval (CI) | Weighted count \\*\\* (n) |   |\n|---|---|---|---|---|\n| **Overall rate** | 11\\.3 | 10\\.3-12.4 | 902,700 |   |\n| Age (years) | 18-34 | 11\\.1 | 9\\.1-13.1 | 326,500 |\n| 35-49 | 10\\.9 | 9\\.2-12.7 | 270,400 |   |\n| 50-64 | 12\\.5 | 10\\.4-14.5 | 226,500 |   |\n| 65+ | 10\\.8 | 8\\.0-13.6 | 79,200 |   |\n| Sex | Female | 14\\.5 | 12\\.9-16.1 | 576,800 |\n| Male | 8\\.2 | 6\\.8-9.6 | 325,900 |   |\n| Ethnoracial group | Indigenous identity group | 21\\.2 | 13\\.7-28.7 | 57,200 |\n| Non-racialized group§ | 11\\.9 | 10\\.7-13.2 | 667,200 |   |\n| Racialized group¥ | 8\\.4 | 6\\.2-10.6 | 175,900 |   |\n\n§ Non-racialized group- all respondents who identified as White, excluding those who identified as Indigenous\n\n¥ Racialized group- all respondents who did not identify as Indigenous or White\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n***\n![medical chart icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/medicalchart.png)\n\n## Among adults with a history of mental health condition or chronic neurological disorder\nAdults were more likely to report long-term neuropsychiatric symptoms if they had a history of:\n\n- mental health condition (e.g., depression, anxiety)\n- chronic neurological disorder (e.g., Alzheimer's disease or other dementia, and other neurological conditions)\n\nThe percentage reporting long-term neuropsychiatric symptoms was:\n\n- 2\\.0 times higher among those with a history of mental health condition (20.3%) than those without a history (10.2%)\n- 2\\.4 times higher among those with a history of chronic neurological disorder (26.3%E) than those without a history (11.1%) (Table 2)\n\nTable 2. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by history of mental health condition or chronic neurological disorder.\n\n| Having a history of | Response | Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) | 95% Confidence Interval (CI) | Weighted count\\*\\* (n) |\n|---|---|---|---|---|\n| Mental health condition | Yes | 20\\.3 | 16\\.4-24.6 | 183,000 |\n| No | 10\\.2 | 9\\.1-11.4 | 719,700 |   |\n| Chronic neurological disorder | Yes | 26\\.3E | 14\\.7-41.0E | 31,500 |\n| No | 11\\.1 | 10\\.1-12.2 | 871,200 |   |\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n\nE Results should be interpreted with caution due to high sampling variability.\n***\n![hospital icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/hospital.png)\n\n## Among adults with difficulties accessing healthcare\nThe survey asked respondents if they had difficulties accessing healthcare services in the last 12 months. Across most categories, adults who experienced difficulties were more likely to report long-term neuropsychiatric symptoms (Table 3).\n\nThe percentage reporting long-term neuropsychiatric symptoms was 2.2 times higher among those who had any difficulty accessing healthcare services (17.0%) than those who did not (7.6%) (Table 3).\n\nThe most common difficulties were:\n\n- lack of availability of culturally appropriate health services (25.3%E)\n- cost issues (23.1%E)\n- transportation issues (23.0%E)\n- unavailability of healthcare services in the residential area (22.4%)\n\nTable 3. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by difficulties accessing healthcare services.\n\n| Difficulties accessing healthcare services | Response | Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) | 95% Confidence Interval (CI) | Weighted count\\*\\* (n) |\n|---|---|---|---|---|\n| Any difficulty | Yes | 17\\.0 | 15\\.0-19.1 | 537,800 |\n| No | 7\\.6 | 6\\.5-8.8 | 364,900 |   |\n| Lack of availability of culturally appropriate health services | Yes | 25\\.3E | 11\\.2-44.7E | 18,800 |\n| No | 11\\.4 | 10\\.3-12.5 | 863,100 |   |\n| Cost issues | Yes | 23\\.1E | 16\\.3-31.2E | 89,900 |\n| No | 10\\.9 | 9\\.8-12.0 | 792,000 |   |\n| Transportation issues | Yes | 23\\.0E | 13\\.1-35.6E | 31,300 |\n| No | 11\\.3 | 10\\.2-12.4 | 850,600 |   |\n| Not available in my area | Yes | 22\\.4 | 16\\.5-29.3 | 92,000 |\n| No | 10\\.9 | 9\\.8-12.0 | 789,900 |   |\n| Quarantine or office closures | Yes | 21\\.0 | 16\\.7-25.9 | 191,500 |\n| No | 10\\.2 | 9\\.2-11.3 | 690,300 |   |\n| Appointment cancellation, delay or rescheduling due to non-COVID-19 pandemic reasons | Yes | 20\\.3 | 14\\.8-26.8 | 117,000 |\n| No | 10\\.8 | 9\\.7-11.9 | 764,800 |   |\n| Appointment cancellation, delay or rescheduling due to COVID-19 pandemic | Yes | 19\\.3 | 16\\.0-22.9 | 285,500 |\n| No | 9\\.6 | 8\\.5-10.8 | 596,300 |   |\n| Waited too long between booking appointments and services | Yes | 18\\.0 | 14\\.9-21.4 | 252,400 |\n| No | 10\\.0 | 8\\.9-11.2 | 629,500 |   |\n| Difficulty getting a referral | Yes | 16\\.3 | 12\\.6-20.6 | 134,500 |\n| No | 10\\.9 | 9\\.8-12.1 | 747,400 |   |\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n\nE Results should be interpreted with caution due to high sampling variability.\n***\n![severity icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/time1.png)\n\n## Severity of COVID-19 symptoms\nAdults with more severe initial COVID-19 symptoms were more likely to have long-term neuropsychiatric symptoms (Table 4). The percentage of those who had long-term neuropsychiatric symptoms was:\n\n- 27\\.8% among those who reported severe COVID-19 symptoms\n- 11\\.5% among those who reported moderate COVID-19 symptoms\n- 4\\.4% among those who reported mild COVID-19 symptoms\n\nTable 4. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by severity of initial COVID-19 symptoms.\n\n| Impact of COVID-19 | Response | Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) | 95% Confidence Interval (CI) | Weighted count\\*\\* (n) |\n|---|---|---|---|---|\n| Severity of initial COVID-19 symptoms | Mild symptoms- no effect on daily life | 4\\.4 | 3\\.3-5.7 | 114,000 |\n| Moderate symptoms- some effect on daily life | 11\\.5 | 9\\.8-13.3 | 391,100 |   |\n| Severe symptoms- significant effect on daily life | 27\\.8 | 24\\.3-31.6 | 386,400 |   |\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n***\n![population icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/subset.png)\n\n## Subset population with neuropsychiatric symptoms\nThe data below come from the subset of people who experienced neuropsychiatric symptoms of COVID-19. This is different from other data in this blog, which come from the larger group of people with a COVID-19 infection 3 or more months prior to the survey.\n\n### Limitations to daily activities from COVID-19 symptoms\nThe survey asked about limitations to daily activities from COVID-19 symptoms. 1 in 4 (23.8%) adults with long-term neuropsychiatric symptoms were often or always limited in daily activities by their symptoms (Table 5).\n\n### Accessing healthcare for COVID-19 symptoms\nSome respondents reported difficulty accessing healthcare (Table 3). These respondents were also asked about accessing healthcare services for COVID-19 symptoms. 4 in 10 (39.8%) adults with long-term neuropsychiatric symptoms reported experiencing difficulties (Table 5).\n\nTable 5. Percentage of adults with long-term neuropsychiatric symptoms of COVID-19 reporting limitations to daily activities due to COVID-19 symptoms and difficulties accessing healthcare for COVID-19 symptoms in the last 12 months.\n\n| Impact of COVID-19 | Response | Percentage (%) | 95% Confidence Interval (CI) | Weighted Count\\*\\* (n) |\n|---|---|---|---|---|\n| Limitations to daily activities due to COVID-19 symptoms | Never | 13\\.2 | 9\\.9-17.0 | 118,800 |\n| Rarely or sometimes | 6\\.7 | 57\\.7-67.6 | 566,300 |   |\n| Often or always | 23\\.8 | 19\\.8-28.2 | 215,100 |   |\n| Difficulties accessing healthcare services for COVID-19 symptoms in the last 12 months | Yes | 39\\.8 | 33\\.4-46.9 | 213,700 |\n| No | 60\\.2 | 53\\.6-66.6 | 323,600 |   |\n\n\\*\\* Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population.\n***\n![medical help icon](https:\/\/health-infobase.canada.ca\/src\/img\/pcc-neuropsychiatric-symptoms\/help.png)\n\nOn May 5, 2023, the World Health Organization declared that COVID-19 is an established and ongoing health issue that no longer constitutes a global health threat. While it is no longer classified as a public health emergency, many people living in Canada continue to be affected by COVID-19. If you or someone close to you is experiencing long-term symptoms of COVID-19, including neuropsychiatric symptoms, it is important to talk to a health care provider.\n## For more information on long-term symptoms of COVID-19\n- [Post-COVID-19 condition (long COVID)](https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/2019-novel-coronavirus-infection\/symptoms\/post-covid-19-condition.html)\n- [COVID-19 longer-term symptoms among Canadian adults](https:\/\/health-infobase.canada.ca\/covid-19\/post-covid-condition\/)\n- [COVID-19 epidemiology update: Summary](https:\/\/health-infobase.canada.ca\/covid-19\/)\n## About the data\nThis blog uses national data from the [Canadian COVID-19 Antibody and Health Survey (CCAHS) – Cycle 2](https:\/\/www.statcan.gc.ca\/en\/survey\/household\/5339), collected by Statistics Canada. The survey collected information between April and August 2022. Data is from adults 18 years and older living in Canada. Unless otherwise noted, data is from adults who self-reported a COVID-19 infection 3 or more months before the survey. COVID-19 infections could be confirmed by a test or suspected from experienced symptoms or known exposures.\n\nA weight was assigned to each respondent of the survey, so the results accurately represent the Canadian population. A **weighted count** uses these assigned weights and is not the actual number of survey respondents.\n\nPopulations excluded from the CCAHS-2 were people:\n\n- living in the three territories\n- less than 18 years old\n- living on reserves and other Indigenous settlements in the provinces\n- living in institutions\n- full-time members of the Canadian Forces living on base\n- residents in certain remote regions\n\nFor more information on the CCAHS-2, visit [Canadian COVID-19 Antibody and Health Survey (CCAHS)-Cycle 2](https:\/\/www.statcan.gc.ca\/en\/survey\/household\/5339).\n\n### Suggested citation\nLong-term neuropsychiatric symptoms of COVID-19 among adults. Data from the Canadian COVID-19 Antibody and Health Survey – Cycle 2 April to August 2022. Public Health Agency of Canada, Centre for Surveillance and Applied Research. 2024.\n***\nThank you for your feedback\n\nDate modified:\n\n2024-10-30","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

14 days ago

🚫

ROBOTS BLOCKED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0.5 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html
Last Crawled	2026-04-02 16:03:13 (14 days ago)
First Indexed	not set
HTTP Status Code	200
Meta Title	Long-term neuropsychiatric symptoms of COVID-19 among adults — Canada.ca
Meta Description	Data from the Canadian COVID-19 Antibody and Health Survey - Cycle 2 April to August 2022.
Meta Canonical	null
Boilerpipe Text	Most people will experience and recover from initial symptoms of COVID-19 illness. Some will develop ongoing symptoms more than 3 months after their COVID-19 infection Footnote 1 . Long-term symptoms of COVID-19 can be grouped into two major categories Footnote 2 , Footnote 3 : cardiopulmonary - related to the heart and lungs neuropsychiatric - related to the nervous system, cognitive function (such as thinking, reasoning, memory, and judgement) and mental health Neuropsychiatric symptoms are more common. Two-thirds of adults experiencing long-term symptoms of COVID-19 report neuropsychiatric symptoms. For this survey, data on the following neuropsychiatric symptoms were collected: difficulty thinking and solving problems (brain fog) stress or anxiety sadness, negativity, hopelessness, or depression headache loss of taste or smell There are other long-term neuropsychiatric symptoms of COVID-19 not captured in the survey. These 5 are the most commonly reported symptoms. Rate of long-term neuropsychiatric symptoms of COVID-19 More than 1 in 10 (11.3%, weighted count of 902,700) adults experienced long-term neuropsychiatric symptoms (Table 1). Rate by socio-demographic group We examined the rate of long-term neuropsychiatric symptoms across different socio-demographic groups. Age A similar percentage of adults across age groups reported long-term neuropsychiatric symptoms. People aged 50 to 64 had the highest rate (12.5%). Differences between age groups were not statistically significant (Table 1). Sex Females (14.5%) were 1.8 times more likely to report long-term neuropsychiatric symptoms than males (8.2%) (Table 1). Ethnoracial group The Indigenous identity group had the highest rate of long-term neuropsychiatric symptoms (21.2%) (Table 1). The rate was: 1.8 times higher than the Non-racialized group (11.9%) 2.5 times higher than the Racialized group (8.4%) Table 1. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by socio-demographic characteristics. Table 1. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by socio-demographic characteristics. Characteristic Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) 95% Confidence interval (CI) Weighted count (n) Overall rate 11.3 10.3-12.4 902,700 Age (years) 18-34 11.1 9.1-13.1 326,500 35-49 10.9 9.2-12.7 270,400 50-64 12.5 10.4-14.5 226,500 65+ 10.8 8.0-13.6 79,200 Sex Female 14.5 12.9-16.1 576,800 Male 8.2 6.8-9.6 325,900 Ethnoracial group Indigenous identity group 21.2 13.7-28.7 57,200 Non-racialized group § 11.9 10.7-13.2 667,200 Racialized group ¥ 8.4 6.2-10.6 175,900 § Non-racialized group- all respondents who identified as White, excluding those who identified as Indigenous ¥ Racialized group- all respondents who did not identify as Indigenous or White Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. Among adults with a history of mental health condition or chronic neurological disorder Adults were more likely to report long-term neuropsychiatric symptoms if they had a history of: mental health condition (e.g., depression, anxiety) chronic neurological disorder (e.g., Alzheimer's disease or other dementia, and other neurological conditions) The percentage reporting long-term neuropsychiatric symptoms was: 2.0 times higher among those with a history of mental health condition (20.3%) than those without a history (10.2%) 2.4 times higher among those with a history of chronic neurological disorder (26.3% E ) than those without a history (11.1%) (Table 2) Table 2. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by history of mental health condition or chronic neurological disorder. Table 2. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by history of mental health condition or chronic neurological disorder. Having a history of Response Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) 95% Confidence Interval (CI) Weighted count (n) Mental health condition Yes 20.3 16.4-24.6 183,000 No 10.2 9.1-11.4 719,700 Chronic neurological disorder Yes 26.3 E 14.7-41.0 E 31,500 No 11.1 10.1-12.2 871,200 Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. E Results should be interpreted with caution due to high sampling variability. Among adults with difficulties accessing healthcare The survey asked respondents if they had difficulties accessing healthcare services in the last 12 months. Across most categories, adults who experienced difficulties were more likely to report long-term neuropsychiatric symptoms (Table 3). The percentage reporting long-term neuropsychiatric symptoms was 2.2 times higher among those who had any difficulty accessing healthcare services (17.0%) than those who did not (7.6%) (Table 3). The most common difficulties were: lack of availability of culturally appropriate health services (25.3% E ) cost issues (23.1% E ) transportation issues (23.0% E ) unavailability of healthcare services in the residential area (22.4%) Table 3. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by difficulties accessing healthcare services. Table 3. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by difficulties accessing healthcare services. Difficulties accessing healthcare services Response Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) 95% Confidence Interval (CI) Weighted count (n) Any difficulty Yes 17.0 15.0-19.1 537,800 No 7.6 6.5-8.8 364,900 Lack of availability of culturally appropriate health services Yes 25.3 E 11.2-44.7 E 18,800 No 11.4 10.3-12.5 863,100 Cost issues Yes 23.1 E 16.3-31.2 E 89,900 No 10.9 9.8-12.0 792,000 Transportation issues Yes 23.0 E 13.1-35.6 E 31,300 No 11.3 10.2-12.4 850,600 Not available in my area Yes 22.4 16.5-29.3 92,000 No 10.9 9.8-12.0 789,900 Quarantine or office closures Yes 21.0 16.7-25.9 191,500 No 10.2 9.2-11.3 690,300 Appointment cancellation, delay or rescheduling due to non-COVID-19 pandemic reasons Yes 20.3 14.8-26.8 117,000 No 10.8 9.7-11.9 764,800 Appointment cancellation, delay or rescheduling due to COVID-19 pandemic Yes 19.3 16.0-22.9 285,500 No 9.6 8.5-10.8 596,300 Waited too long between booking appointments and services Yes 18.0 14.9-21.4 252,400 No 10.0 8.9-11.2 629,500 Difficulty getting a referral Yes 16.3 12.6-20.6 134,500 No 10.9 9.8-12.1 747,400 Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. E Results should be interpreted with caution due to high sampling variability. Severity of COVID-19 symptoms Adults with more severe initial COVID-19 symptoms were more likely to have long-term neuropsychiatric symptoms (Table 4). The percentage of those who had long-term neuropsychiatric symptoms was: 27.8% among those who reported severe COVID-19 symptoms 11.5% among those who reported moderate COVID-19 symptoms 4.4% among those who reported mild COVID-19 symptoms Table 4. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by severity of initial COVID-19 symptoms. Table 4. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by severity of initial COVID-19 symptoms. Impact of COVID-19 Response Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) 95% Confidence Interval (CI) Weighted count (n) Severity of initial COVID-19 symptoms Mild symptoms- no effect on daily life 4.4 3.3-5.7 114,000 Moderate symptoms- some effect on daily life 11.5 9.8-13.3 391,100 Severe symptoms- significant effect on daily life 27.8 24.3-31.6 386,400 Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. Subset population with neuropsychiatric symptoms The data below come from the subset of people who experienced neuropsychiatric symptoms of COVID-19. This is different from other data in this blog, which come from the larger group of people with a COVID-19 infection 3 or more months prior to the survey. Limitations to daily activities from COVID-19 symptoms The survey asked about limitations to daily activities from COVID-19 symptoms. 1 in 4 (23.8%) adults with long-term neuropsychiatric symptoms were often or always limited in daily activities by their symptoms (Table 5). Accessing healthcare for COVID-19 symptoms Some respondents reported difficulty accessing healthcare (Table 3). These respondents were also asked about accessing healthcare services for COVID-19 symptoms. 4 in 10 (39.8%) adults with long-term neuropsychiatric symptoms reported experiencing difficulties (Table 5). Table 5. Percentage of adults with long-term neuropsychiatric symptoms of COVID-19 reporting limitations to daily activities due to COVID-19 symptoms and difficulties accessing healthcare for COVID-19 symptoms in the last 12 months. Table 5. Percentage of adults with long-term neuropsychiatric symptoms of COVID-19 reporting limitations to daily activities due to COVID-19 symptoms and difficulties accessing healthcare for COVID-19 symptoms in the last 12 months. Impact of COVID-19 Response Percentage (%) 95% Confidence Interval (CI) Weighted Count (n) Limitations to daily activities due to COVID-19 symptoms Never 13.2 9.9-17.0 118,800 Rarely or sometimes 6.7 57.7-67.6 566,300 Often or always 23.8 19.8-28.2 215,100 Difficulties accessing healthcare services for COVID-19 symptoms in the last 12 months Yes 39.8 33.4-46.9 213,700 No 60.2 53.6-66.6 323,600 Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. On May 5, 2023, the World Health Organization declared that COVID-19 is an established and ongoing health issue that no longer constitutes a global health threat. While it is no longer classified as a public health emergency, many people living in Canada continue to be affected by COVID-19. If you or someone close to you is experiencing long-term symptoms of COVID-19, including neuropsychiatric symptoms, it is important to talk to a health care provider. For more information on long-term symptoms of COVID-19 Post-COVID-19 condition (long COVID) COVID-19 longer-term symptoms among Canadian adults COVID-19 epidemiology update: Summary About the data This blog uses national data from the Canadian COVID-19 Antibody and Health Survey (CCAHS) – Cycle 2 , collected by Statistics Canada. The survey collected information between April and August 2022. Data is from adults 18 years and older living in Canada. Unless otherwise noted, data is from adults who self-reported a COVID-19 infection 3 or more months before the survey. COVID-19 infections could be confirmed by a test or suspected from experienced symptoms or known exposures. A weight was assigned to each respondent of the survey, so the results accurately represent the Canadian population. A weighted count uses these assigned weights and is not the actual number of survey respondents. Populations excluded from the CCAHS-2 were people: living in the three territories less than 18 years old living on reserves and other Indigenous settlements in the provinces living in institutions full-time members of the Canadian Forces living on base residents in certain remote regions For more information on the CCAHS-2, visit Canadian COVID-19 Antibody and Health Survey (CCAHS)-Cycle 2 . Suggested citation Long-term neuropsychiatric symptoms of COVID-19 among adults. Data from the Canadian COVID-19 Antibody and Health Survey – Cycle 2 April to August 2022. Public Health Agency of Canada, Centre for Surveillance and Applied Research. 2024. Thank you for your feedback Date modified: 2024-10-30
Markdown	- [Skip to main content](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#wb-cont) - [Skip to "About government"](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#wb-info) ## Language selection - [Français](https://sante-infobase.canada.ca/labo-de-donnees/symptomes-neuropsychiatriques-syndrome-post-covid.html) [![](https://health-infobase.canada.ca/src/GCWeb/assets/sig-blk-en.svg) Government of Canada / Gouvernement du Canada](https://www.canada.ca/en.html) ## Search ## You are here: 1. [Canada.ca](https://www.canada.ca/en.html) 2. [Health](https://www.canada.ca/en/services/health.html) 3. [Health science, research and data](https://www.canada.ca/en/services/health/science-research-data.html) 4. [Health Infobase](https://health-infobase.canada.ca/) # Long-term neuropsychiatric symptoms of COVID-19 among adults:Data blog Data from the Canadian COVID-19 Antibody and Health Survey - Cycle 2 April to August 2022. - Last updated: 2024-10-30 ![COVID icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/COVID3.png) Most people will experience and recover from initial symptoms of COVID-19 illness. Some will develop ongoing symptoms more than 3 months after their COVID-19 infection[Footnote 1](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn1 "Post-COVID-19 condition. Annual Review of Medicine."). Long-term symptoms of COVID-19 can be grouped into two major categories[Footnote2](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn2 "Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The Lancet Psychiatry. 2022 Oct 1;9(10):815-27."),[Footnote 3](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn3 "Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness. The Lancet Respiratory Medicine. 2023 Aug 1;11(8):726-38."): - cardiopulmonary - related to the heart and lungs - neuropsychiatric - related to the nervous system, cognitive function (such as thinking, reasoning, memory, and judgement) and mental health Neuropsychiatric symptoms are more common. Two-thirds of adults experiencing long-term symptoms of COVID-19 report neuropsychiatric symptoms. * ![COVID icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/COVID2.png) ## About long-term neuropsychiatric symptoms of COVID-19 For this survey, data on the following neuropsychiatric symptoms were collected: - difficulty thinking and solving problems (brain fog) - stress or anxiety - sadness, negativity, hopelessness, or depression - headache - loss of taste or smell There are other long-term neuropsychiatric symptoms of COVID-19 not captured in the survey. These 5 are the most commonly reported symptoms. * ![population icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/population2.png) ## Rate of long-term neuropsychiatric symptoms of COVID-19 More than 1 in 10 (11.3%, weighted count of 902,700) adults experienced long-term neuropsychiatric symptoms (Table 1). ### Rate by socio-demographic group We examined the rate of long-term neuropsychiatric symptoms across different socio-demographic groups. #### Age A similar percentage of adults across age groups reported long-term neuropsychiatric symptoms. People aged 50 to 64 had the highest rate (12.5%). Differences between age groups were not statistically significant (Table 1). #### Sex Females (14.5%) were 1.8 times more likely to report long-term neuropsychiatric symptoms than males (8.2%) (Table 1). #### Ethnoracial group The Indigenous identity group had the highest rate of long-term neuropsychiatric symptoms (21.2%) (Table 1). The rate was: - 1\.8 times higher than the Non-racialized group (11.9%) - 2\.5 times higher than the Racialized group (8.4%) Table 1. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by socio-demographic characteristics. \| Characteristic \| Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) \| 95% Confidence interval (CI) \| Weighted count \\ (n) \| \| \|---\|---\|---\|---\|---\| \| Overall rate \| 11\.3 \| 10\.3-12.4 \| 902,700 \| \| \| Age (years) \| 18-34 \| 11\.1 \| 9\.1-13.1 \| 326,500 \| \| 35-49 \| 10\.9 \| 9\.2-12.7 \| 270,400 \| \| \| 50-64 \| 12\.5 \| 10\.4-14.5 \| 226,500 \| \| \| 65+ \| 10\.8 \| 8\.0-13.6 \| 79,200 \| \| \| Sex \| Female \| 14\.5 \| 12\.9-16.1 \| 576,800 \| \| Male \| 8\.2 \| 6\.8-9.6 \| 325,900 \| \| \| Ethnoracial group \| Indigenous identity group \| 21\.2 \| 13\.7-28.7 \| 57,200 \| \| Non-racialized group§ \| 11\.9 \| 10\.7-13.2 \| 667,200 \| \| \| Racialized group¥ \| 8\.4 \| 6\.2-10.6 \| 175,900 \| \| § Non-racialized group- all respondents who identified as White, excluding those who identified as Indigenous ¥ Racialized group- all respondents who did not identify as Indigenous or White \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. *** ![medical chart icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/medicalchart.png) ## Among adults with a history of mental health condition or chronic neurological disorder Adults were more likely to report long-term neuropsychiatric symptoms if they had a history of: - mental health condition (e.g., depression, anxiety) - chronic neurological disorder (e.g., Alzheimer's disease or other dementia, and other neurological conditions) The percentage reporting long-term neuropsychiatric symptoms was: - 2\.0 times higher among those with a history of mental health condition (20.3%) than those without a history (10.2%) - 2\.4 times higher among those with a history of chronic neurological disorder (26.3%E) than those without a history (11.1%) (Table 2) Table 2. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by history of mental health condition or chronic neurological disorder. \| Having a history of \| Response \| Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) \| 95% Confidence Interval (CI) \| Weighted count\\ (n) \| \|---\|---\|---\|---\|---\| \| Mental health condition \| Yes \| 20\.3 \| 16\.4-24.6 \| 183,000 \| \| No \| 10\.2 \| 9\.1-11.4 \| 719,700 \| \| \| Chronic neurological disorder \| Yes \| 26\.3E \| 14\.7-41.0E \| 31,500 \| \| No \| 11\.1 \| 10\.1-12.2 \| 871,200 \| \| \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. E Results should be interpreted with caution due to high sampling variability. *** ![hospital icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/hospital.png) ## Among adults with difficulties accessing healthcare The survey asked respondents if they had difficulties accessing healthcare services in the last 12 months. Across most categories, adults who experienced difficulties were more likely to report long-term neuropsychiatric symptoms (Table 3). The percentage reporting long-term neuropsychiatric symptoms was 2.2 times higher among those who had any difficulty accessing healthcare services (17.0%) than those who did not (7.6%) (Table 3). The most common difficulties were: - lack of availability of culturally appropriate health services (25.3%E) - cost issues (23.1%E) - transportation issues (23.0%E) - unavailability of healthcare services in the residential area (22.4%) Table 3. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by difficulties accessing healthcare services. \| Difficulties accessing healthcare services \| Response \| Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) \| 95% Confidence Interval (CI) \| Weighted count\\ (n) \| \|---\|---\|---\|---\|---\| \| Any difficulty \| Yes \| 17\.0 \| 15\.0-19.1 \| 537,800 \| \| No \| 7\.6 \| 6\.5-8.8 \| 364,900 \| \| \| Lack of availability of culturally appropriate health services \| Yes \| 25\.3E \| 11\.2-44.7E \| 18,800 \| \| No \| 11\.4 \| 10\.3-12.5 \| 863,100 \| \| \| Cost issues \| Yes \| 23\.1E \| 16\.3-31.2E \| 89,900 \| \| No \| 10\.9 \| 9\.8-12.0 \| 792,000 \| \| \| Transportation issues \| Yes \| 23\.0E \| 13\.1-35.6E \| 31,300 \| \| No \| 11\.3 \| 10\.2-12.4 \| 850,600 \| \| \| Not available in my area \| Yes \| 22\.4 \| 16\.5-29.3 \| 92,000 \| \| No \| 10\.9 \| 9\.8-12.0 \| 789,900 \| \| \| Quarantine or office closures \| Yes \| 21\.0 \| 16\.7-25.9 \| 191,500 \| \| No \| 10\.2 \| 9\.2-11.3 \| 690,300 \| \| \| Appointment cancellation, delay or rescheduling due to non-COVID-19 pandemic reasons \| Yes \| 20\.3 \| 14\.8-26.8 \| 117,000 \| \| No \| 10\.8 \| 9\.7-11.9 \| 764,800 \| \| \| Appointment cancellation, delay or rescheduling due to COVID-19 pandemic \| Yes \| 19\.3 \| 16\.0-22.9 \| 285,500 \| \| No \| 9\.6 \| 8\.5-10.8 \| 596,300 \| \| \| Waited too long between booking appointments and services \| Yes \| 18\.0 \| 14\.9-21.4 \| 252,400 \| \| No \| 10\.0 \| 8\.9-11.2 \| 629,500 \| \| \| Difficulty getting a referral \| Yes \| 16\.3 \| 12\.6-20.6 \| 134,500 \| \| No \| 10\.9 \| 9\.8-12.1 \| 747,400 \| \| \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. E Results should be interpreted with caution due to high sampling variability. *** ![severity icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/time1.png) ## Severity of COVID-19 symptoms Adults with more severe initial COVID-19 symptoms were more likely to have long-term neuropsychiatric symptoms (Table 4). The percentage of those who had long-term neuropsychiatric symptoms was: - 27\.8% among those who reported severe COVID-19 symptoms - 11\.5% among those who reported moderate COVID-19 symptoms - 4\.4% among those who reported mild COVID-19 symptoms Table 4. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by severity of initial COVID-19 symptoms. \| Impact of COVID-19 \| Response \| Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) \| 95% Confidence Interval (CI) \| Weighted count\\ (n) \| \|---\|---\|---\|---\|---\| \| Severity of initial COVID-19 symptoms \| Mild symptoms- no effect on daily life \| 4\.4 \| 3\.3-5.7 \| 114,000 \| \| Moderate symptoms- some effect on daily life \| 11\.5 \| 9\.8-13.3 \| 391,100 \| \| \| Severe symptoms- significant effect on daily life \| 27\.8 \| 24\.3-31.6 \| 386,400 \| \| \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. *** ![population icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/subset.png) ## Subset population with neuropsychiatric symptoms The data below come from the subset of people who experienced neuropsychiatric symptoms of COVID-19. This is different from other data in this blog, which come from the larger group of people with a COVID-19 infection 3 or more months prior to the survey. ### Limitations to daily activities from COVID-19 symptoms The survey asked about limitations to daily activities from COVID-19 symptoms. 1 in 4 (23.8%) adults with long-term neuropsychiatric symptoms were often or always limited in daily activities by their symptoms (Table 5). ### Accessing healthcare for COVID-19 symptoms Some respondents reported difficulty accessing healthcare (Table 3). These respondents were also asked about accessing healthcare services for COVID-19 symptoms. 4 in 10 (39.8%) adults with long-term neuropsychiatric symptoms reported experiencing difficulties (Table 5). Table 5. Percentage of adults with long-term neuropsychiatric symptoms of COVID-19 reporting limitations to daily activities due to COVID-19 symptoms and difficulties accessing healthcare for COVID-19 symptoms in the last 12 months. \| Impact of COVID-19 \| Response \| Percentage (%) \| 95% Confidence Interval (CI) \| Weighted Count\\ (n) \| \|---\|---\|---\|---\|---\| \| Limitations to daily activities due to COVID-19 symptoms \| Never \| 13\.2 \| 9\.9-17.0 \| 118,800 \| \| Rarely or sometimes \| 6\.7 \| 57\.7-67.6 \| 566,300 \| \| \| Often or always \| 23\.8 \| 19\.8-28.2 \| 215,100 \| \| \| Difficulties accessing healthcare services for COVID-19 symptoms in the last 12 months \| Yes \| 39\.8 \| 33\.4-46.9 \| 213,700 \| \| No \| 60\.2 \| 53\.6-66.6 \| 323,600 \| \| \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. * ![medical help icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/help.png) On May 5, 2023, the World Health Organization declared that COVID-19 is an established and ongoing health issue that no longer constitutes a global health threat. While it is no longer classified as a public health emergency, many people living in Canada continue to be affected by COVID-19. If you or someone close to you is experiencing long-term symptoms of COVID-19, including neuropsychiatric symptoms, it is important to talk to a health care provider. ## For more information on long-term symptoms of COVID-19 - [Post-COVID-19 condition (long COVID)](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html) - [COVID-19 longer-term symptoms among Canadian adults](https://health-infobase.canada.ca/covid-19/post-covid-condition/) - [COVID-19 epidemiology update: Summary](https://health-infobase.canada.ca/covid-19/) ## About the data This blog uses national data from the [Canadian COVID-19 Antibody and Health Survey (CCAHS) – Cycle 2](https://www.statcan.gc.ca/en/survey/household/5339), collected by Statistics Canada. The survey collected information between April and August 2022. Data is from adults 18 years and older living in Canada. Unless otherwise noted, data is from adults who self-reported a COVID-19 infection 3 or more months before the survey. COVID-19 infections could be confirmed by a test or suspected from experienced symptoms or known exposures. A weight was assigned to each respondent of the survey, so the results accurately represent the Canadian population. A weighted count uses these assigned weights and is not the actual number of survey respondents. Populations excluded from the CCAHS-2 were people: - living in the three territories - less than 18 years old - living on reserves and other Indigenous settlements in the provinces - living in institutions - full-time members of the Canadian Forces living on base - residents in certain remote regions For more information on the CCAHS-2, visit [Canadian COVID-19 Antibody and Health Survey (CCAHS)-Cycle 2](https://www.statcan.gc.ca/en/survey/household/5339). ### Suggested citation Long-term neuropsychiatric symptoms of COVID-19 among adults. Data from the Canadian COVID-19 Antibody and Health Survey – Cycle 2 April to August 2022. Public Health Agency of Canada, Centre for Surveillance and Applied Research. 2024. ## References Reference 1 Nalbandian A, Desai AD, Wan EY. Post-COVID-19 condition. Annual Review of Medicine. 2023 Jan 27; 74: 55-64. [Return to footnote 1 referrer](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn1-rf) Reference 2 Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, Harrison PJ. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The Lancet Psychiatry. 2022 Oct 1;9(10):815-27. [Return to first footnote 2 referrer](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn2-rf) Reference 3 Pandharipande P, Roberson SW, Harrison FE, Wilson JE, Bastarache JA, Ely EW. Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness. The Lancet Respiratory Medicine. 2023 Aug 1;11(8):726-38. [Return to first footnote 3 referrer](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn3-rf) * ## You might also be interested in ![](https://health-infobase.canada.ca/src/img/redesign/covid.png) ### [COVID-19: Longer-term symptoms among Canadian adults](https://health-infobase.canada.ca/covid-19/post-covid-condition/) Data on longer-term symptoms of COVID-19 in Canada. ![](https://health-infobase.canada.ca/src/img/redesign/covid.png) ### [COVID-19 epidemiology update: Summary](https://health-infobase.canada.ca/covid-19/) Summary of COVID-19 cases, hospitalizations and deaths, testing and variants of concern, and outbreaks across Canada. [All Health Infobase data products](https://health-infobase.canada.ca/) Thank you for your feedback Date modified: 2024-10-30 ## About this site ### [Health Infobase](https://health-infobase.canada.ca/) - [Contact us by email](mailto:infobase@phac-aspc.gc.ca) ### Government of Canada - [All Contacts](https://www.canada.ca/en/contact.html) - [Departments and agencies](https://www.canada.ca/en/government/dept.html) - [About government](https://www.canada.ca/en/government/system.html) #### Themes and topics - [Jobs](https://www.canada.ca/en/services/jobs.html) - [Immigration and citizenship](https://www.canada.ca/en/services/immigration-citizenship.html) - [Travel and tourism](https://travel.gc.ca/) - [Business](https://www.canada.ca/en/services/business.html) - [Benefits](https://www.canada.ca/en/services/benefits.html) - [Health](https://www.canada.ca/en/services/health.html) - [Taxes](https://www.canada.ca/en/services/taxes.html) - [Environment and natural resources](https://www.canada.ca/en/services/environment.html) - [National security and defence](https://www.canada.ca/en/services/defence.html) - [Culture, history and sport](https://www.canada.ca/en/services/culture.html) - [Policing, justice and emergencies](https://www.canada.ca/en/services/policing.html) - [Transport and infrastructure](https://www.canada.ca/en/services/transport.html) - [Canada and the world](https://international.gc.ca/world-monde/index.aspx?lang=eng) - [Money and finance](https://www.canada.ca/en/services/finance.html) - [Science and innovation](https://www.canada.ca/en/services/science.html) - [Indigenous peoples](https://www.canada.ca/en/services/indigenous-peoples.html) - [Veterans and military](https://www.canada.ca/en/services/veterans.html) - [Youth](https://www.canada.ca/en/services/youth.html) ### Government of Canada Corporate - [Social media](https://www.canada.ca/en/social.html) - [Mobile applications](https://www.canada.ca/en/mobile.html) - [About Canada.ca](https://www.canada.ca/en/government/about.html) - [Terms and conditions](https://www.canada.ca/en/transparency/terms.html) - [Privacy](https://www.canada.ca/en/transparency/privacy.html) ![Symbol of the Government of Canada](https://health-infobase.canada.ca/src/assets/wmms-blk.svg)
Readable Markdown	![COVID icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/COVID3.png) Most people will experience and recover from initial symptoms of COVID-19 illness. Some will develop ongoing symptoms more than 3 months after their COVID-19 infection[Footnote 1](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn1 "Post-COVID-19 condition. Annual Review of Medicine."). Long-term symptoms of COVID-19 can be grouped into two major categories[Footnote2](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn2 "Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The Lancet Psychiatry. 2022 Oct 1;9(10):815-27."),[Footnote 3](https://health-infobase.canada.ca/datalab/post-covid-condition-neuropsychiatric-symptoms.html#fn3 "Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness. The Lancet Respiratory Medicine. 2023 Aug 1;11(8):726-38."): - cardiopulmonary - related to the heart and lungs - neuropsychiatric - related to the nervous system, cognitive function (such as thinking, reasoning, memory, and judgement) and mental health Neuropsychiatric symptoms are more common. Two-thirds of adults experiencing long-term symptoms of COVID-19 report neuropsychiatric symptoms. * ![COVID icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/COVID2.png) For this survey, data on the following neuropsychiatric symptoms were collected: - difficulty thinking and solving problems (brain fog) - stress or anxiety - sadness, negativity, hopelessness, or depression - headache - loss of taste or smell There are other long-term neuropsychiatric symptoms of COVID-19 not captured in the survey. These 5 are the most commonly reported symptoms. * ![population icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/population2.png) ## Rate of long-term neuropsychiatric symptoms of COVID-19 More than 1 in 10 (11.3%, weighted count of 902,700) adults experienced long-term neuropsychiatric symptoms (Table 1). ### Rate by socio-demographic group We examined the rate of long-term neuropsychiatric symptoms across different socio-demographic groups. #### Age A similar percentage of adults across age groups reported long-term neuropsychiatric symptoms. People aged 50 to 64 had the highest rate (12.5%). Differences between age groups were not statistically significant (Table 1). #### Sex Females (14.5%) were 1.8 times more likely to report long-term neuropsychiatric symptoms than males (8.2%) (Table 1). #### Ethnoracial group The Indigenous identity group had the highest rate of long-term neuropsychiatric symptoms (21.2%) (Table 1). The rate was: - 1\.8 times higher than the Non-racialized group (11.9%) - 2\.5 times higher than the Racialized group (8.4%) Table 1. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by socio-demographic characteristics. \| Characteristic \| Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) \| 95% Confidence interval (CI) \| Weighted count \\ (n) \| \| \|---\|---\|---\|---\|---\| \| Overall rate \| 11\.3 \| 10\.3-12.4 \| 902,700 \| \| \| Age (years) \| 18-34 \| 11\.1 \| 9\.1-13.1 \| 326,500 \| \| 35-49 \| 10\.9 \| 9\.2-12.7 \| 270,400 \| \| \| 50-64 \| 12\.5 \| 10\.4-14.5 \| 226,500 \| \| \| 65+ \| 10\.8 \| 8\.0-13.6 \| 79,200 \| \| \| Sex \| Female \| 14\.5 \| 12\.9-16.1 \| 576,800 \| \| Male \| 8\.2 \| 6\.8-9.6 \| 325,900 \| \| \| Ethnoracial group \| Indigenous identity group \| 21\.2 \| 13\.7-28.7 \| 57,200 \| \| Non-racialized group§ \| 11\.9 \| 10\.7-13.2 \| 667,200 \| \| \| Racialized group¥ \| 8\.4 \| 6\.2-10.6 \| 175,900 \| \| § Non-racialized group- all respondents who identified as White, excluding those who identified as Indigenous ¥ Racialized group- all respondents who did not identify as Indigenous or White \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. *** ![medical chart icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/medicalchart.png) ## Among adults with a history of mental health condition or chronic neurological disorder Adults were more likely to report long-term neuropsychiatric symptoms if they had a history of: - mental health condition (e.g., depression, anxiety) - chronic neurological disorder (e.g., Alzheimer's disease or other dementia, and other neurological conditions) The percentage reporting long-term neuropsychiatric symptoms was: - 2\.0 times higher among those with a history of mental health condition (20.3%) than those without a history (10.2%) - 2\.4 times higher among those with a history of chronic neurological disorder (26.3%E) than those without a history (11.1%) (Table 2) Table 2. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by history of mental health condition or chronic neurological disorder. \| Having a history of \| Response \| Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) \| 95% Confidence Interval (CI) \| Weighted count\\ (n) \| \|---\|---\|---\|---\|---\| \| Mental health condition \| Yes \| 20\.3 \| 16\.4-24.6 \| 183,000 \| \| No \| 10\.2 \| 9\.1-11.4 \| 719,700 \| \| \| Chronic neurological disorder \| Yes \| 26\.3E \| 14\.7-41.0E \| 31,500 \| \| No \| 11\.1 \| 10\.1-12.2 \| 871,200 \| \| \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. E Results should be interpreted with caution due to high sampling variability. *** ![hospital icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/hospital.png) ## Among adults with difficulties accessing healthcare The survey asked respondents if they had difficulties accessing healthcare services in the last 12 months. Across most categories, adults who experienced difficulties were more likely to report long-term neuropsychiatric symptoms (Table 3). The percentage reporting long-term neuropsychiatric symptoms was 2.2 times higher among those who had any difficulty accessing healthcare services (17.0%) than those who did not (7.6%) (Table 3). The most common difficulties were: - lack of availability of culturally appropriate health services (25.3%E) - cost issues (23.1%E) - transportation issues (23.0%E) - unavailability of healthcare services in the residential area (22.4%) Table 3. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by difficulties accessing healthcare services. \| Difficulties accessing healthcare services \| Response \| Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) \| 95% Confidence Interval (CI) \| Weighted count\\ (n) \| \|---\|---\|---\|---\|---\| \| Any difficulty \| Yes \| 17\.0 \| 15\.0-19.1 \| 537,800 \| \| No \| 7\.6 \| 6\.5-8.8 \| 364,900 \| \| \| Lack of availability of culturally appropriate health services \| Yes \| 25\.3E \| 11\.2-44.7E \| 18,800 \| \| No \| 11\.4 \| 10\.3-12.5 \| 863,100 \| \| \| Cost issues \| Yes \| 23\.1E \| 16\.3-31.2E \| 89,900 \| \| No \| 10\.9 \| 9\.8-12.0 \| 792,000 \| \| \| Transportation issues \| Yes \| 23\.0E \| 13\.1-35.6E \| 31,300 \| \| No \| 11\.3 \| 10\.2-12.4 \| 850,600 \| \| \| Not available in my area \| Yes \| 22\.4 \| 16\.5-29.3 \| 92,000 \| \| No \| 10\.9 \| 9\.8-12.0 \| 789,900 \| \| \| Quarantine or office closures \| Yes \| 21\.0 \| 16\.7-25.9 \| 191,500 \| \| No \| 10\.2 \| 9\.2-11.3 \| 690,300 \| \| \| Appointment cancellation, delay or rescheduling due to non-COVID-19 pandemic reasons \| Yes \| 20\.3 \| 14\.8-26.8 \| 117,000 \| \| No \| 10\.8 \| 9\.7-11.9 \| 764,800 \| \| \| Appointment cancellation, delay or rescheduling due to COVID-19 pandemic \| Yes \| 19\.3 \| 16\.0-22.9 \| 285,500 \| \| No \| 9\.6 \| 8\.5-10.8 \| 596,300 \| \| \| Waited too long between booking appointments and services \| Yes \| 18\.0 \| 14\.9-21.4 \| 252,400 \| \| No \| 10\.0 \| 8\.9-11.2 \| 629,500 \| \| \| Difficulty getting a referral \| Yes \| 16\.3 \| 12\.6-20.6 \| 134,500 \| \| No \| 10\.9 \| 9\.8-12.1 \| 747,400 \| \| \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. E Results should be interpreted with caution due to high sampling variability. *** ![severity icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/time1.png) ## Severity of COVID-19 symptoms Adults with more severe initial COVID-19 symptoms were more likely to have long-term neuropsychiatric symptoms (Table 4). The percentage of those who had long-term neuropsychiatric symptoms was: - 27\.8% among those who reported severe COVID-19 symptoms - 11\.5% among those who reported moderate COVID-19 symptoms - 4\.4% among those who reported mild COVID-19 symptoms Table 4. Percentage reporting long-term neuropsychiatric symptoms of COVID-19 among adults who self-reported a suspected or confirmed COVID-19 infection 3 or more months prior to the survey, by severity of initial COVID-19 symptoms. \| Impact of COVID-19 \| Response \| Percentage reporting long-term neuropsychiatric symptoms of COVID-19 (%) \| 95% Confidence Interval (CI) \| Weighted count\\ (n) \| \|---\|---\|---\|---\|---\| \| Severity of initial COVID-19 symptoms \| Mild symptoms- no effect on daily life \| 4\.4 \| 3\.3-5.7 \| 114,000 \| \| Moderate symptoms- some effect on daily life \| 11\.5 \| 9\.8-13.3 \| 391,100 \| \| \| Severe symptoms- significant effect on daily life \| 27\.8 \| 24\.3-31.6 \| 386,400 \| \| \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. *** ![population icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/subset.png) ## Subset population with neuropsychiatric symptoms The data below come from the subset of people who experienced neuropsychiatric symptoms of COVID-19. This is different from other data in this blog, which come from the larger group of people with a COVID-19 infection 3 or more months prior to the survey. ### Limitations to daily activities from COVID-19 symptoms The survey asked about limitations to daily activities from COVID-19 symptoms. 1 in 4 (23.8%) adults with long-term neuropsychiatric symptoms were often or always limited in daily activities by their symptoms (Table 5). ### Accessing healthcare for COVID-19 symptoms Some respondents reported difficulty accessing healthcare (Table 3). These respondents were also asked about accessing healthcare services for COVID-19 symptoms. 4 in 10 (39.8%) adults with long-term neuropsychiatric symptoms reported experiencing difficulties (Table 5). Table 5. Percentage of adults with long-term neuropsychiatric symptoms of COVID-19 reporting limitations to daily activities due to COVID-19 symptoms and difficulties accessing healthcare for COVID-19 symptoms in the last 12 months. \| Impact of COVID-19 \| Response \| Percentage (%) \| 95% Confidence Interval (CI) \| Weighted Count\\ (n) \| \|---\|---\|---\|---\|---\| \| Limitations to daily activities due to COVID-19 symptoms \| Never \| 13\.2 \| 9\.9-17.0 \| 118,800 \| \| Rarely or sometimes \| 6\.7 \| 57\.7-67.6 \| 566,300 \| \| \| Often or always \| 23\.8 \| 19\.8-28.2 \| 215,100 \| \| \| Difficulties accessing healthcare services for COVID-19 symptoms in the last 12 months \| Yes \| 39\.8 \| 33\.4-46.9 \| 213,700 \| \| No \| 60\.2 \| 53\.6-66.6 \| 323,600 \| \| \\ Each respondent of the survey was assigned a weight to ensure that results accurately represent the overall population. * ![medical help icon](https://health-infobase.canada.ca/src/img/pcc-neuropsychiatric-symptoms/help.png) On May 5, 2023, the World Health Organization declared that COVID-19 is an established and ongoing health issue that no longer constitutes a global health threat. While it is no longer classified as a public health emergency, many people living in Canada continue to be affected by COVID-19. If you or someone close to you is experiencing long-term symptoms of COVID-19, including neuropsychiatric symptoms, it is important to talk to a health care provider. ## For more information on long-term symptoms of COVID-19 - [Post-COVID-19 condition (long COVID)](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html) - [COVID-19 longer-term symptoms among Canadian adults](https://health-infobase.canada.ca/covid-19/post-covid-condition/) - [COVID-19 epidemiology update: Summary](https://health-infobase.canada.ca/covid-19/) ## About the data This blog uses national data from the [Canadian COVID-19 Antibody and Health Survey (CCAHS) – Cycle 2](https://www.statcan.gc.ca/en/survey/household/5339), collected by Statistics Canada. The survey collected information between April and August 2022. Data is from adults 18 years and older living in Canada. Unless otherwise noted, data is from adults who self-reported a COVID-19 infection 3 or more months before the survey. COVID-19 infections could be confirmed by a test or suspected from experienced symptoms or known exposures. A weight was assigned to each respondent of the survey, so the results accurately represent the Canadian population. A weighted count uses these assigned weights and is not the actual number of survey respondents. Populations excluded from the CCAHS-2 were people: - living in the three territories - less than 18 years old - living on reserves and other Indigenous settlements in the provinces - living in institutions - full-time members of the Canadian Forces living on base - residents in certain remote regions For more information on the CCAHS-2, visit [Canadian COVID-19 Antibody and Health Survey (CCAHS)-Cycle 2](https://www.statcan.gc.ca/en/survey/household/5339). ### Suggested citation Long-term neuropsychiatric symptoms of COVID-19 among adults. Data from the Canadian COVID-19 Antibody and Health Survey – Cycle 2 April to August 2022. Public Health Agency of Canada, Centre for Surveillance and Applied Research. 2024. * Thank you for your feedback Date modified: 2024-10-30
Shard	183 (laksa)
Root Hash	10069666093540770583
Unparsed URL	ca,canada!health-infobase,/datalab/post-covid-condition-neuropsychiatric-symptoms.html s443